Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06308718 · ClinicalTrials.gov registry record
Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients
A clinical trial, sponsored by Forge Biologics.
- Terminated
- Registry status
- 2
- Enrollment target
NCT06308718: Clinical Trial study, sponsored by Forge Biologics.
NCT06308718 is a clinical trial that was terminated before completion, run by Forge Biologics. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06308718 was terminated before completion, sponsored by Forge Biologics.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
This is an observational study that will enroll any patients with Krabbe disease that have participated in prior interventional clinical trials involving the administration of FBX-101.
Interventions
- BIOLOGICAL FBX-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2024-08-06 |
| Est. Completion | 2025-04-11 |
Why NCT06308718 stopped before completion
NCT06308718 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which FBX-101 is the first listed.
NCT06308718 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06308718 about?
NCT06308718 is a clinical study titled "Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients". This is an observational study that will enroll any patients with Krabbe disease that have participated in prior interventional clinical trials involving the administration of FBX-101.
What is the current status of trial NCT06308718?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2024-08-06. Estimated completion is 2025-04-11.
What interventions are being tested in trial NCT06308718?
The interventions under investigation include: FBX-101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06308718?
This trial is sponsored by Forge Biologics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI